Bosentan and warfarin interactionMURPHEY, Lisa M; HOOD, Elizabeth H.The Annals of pharmacotherapy. 2003, Vol 37, Num 7-8, pp 1028-1031, issn 1060-0280, 4 p.Article

Orlistat enhances warfarin effectMACWALTER, Ronald S; FRASER, Hazel W; ARMSTRONG, Katherine M et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 4, pp 510-512, issn 1060-0280, 3 p.Article

Interaction between warfarin and the herbal product quilinggaoWONG, Anna L. N; CHAN, Thomas Y. K.The Annals of pharmacotherapy. 2003, Vol 37, Num 6, pp 836-838, issn 1060-0280, 3 p.Article

Assessment of an age-adjusted warfarin initiation protocolROBERTS, Gregory W; HELBOE, Trine; NIELSEN, Cathrine B. M et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 6, pp 799-803, issn 1060-0280, 5 p.Article

Relationship between patients' warfarin knowledge and anticoagulation controlTANG, Elaine Othilia Y. L; LAI, Cemen S. M; LEE, Kenneth K. C et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 1, pp 34-39, issn 1060-0280, 6 p.Article

Plasma S/R ratio of warfarin co-varies with VKORC1 haplotypeOSMAN, Abdimajid; ENSTRÖM, Camilla; LINDAHL, Tomas L et al.Blood coagulation & fibrinolysis. 2007, Vol 18, Num 3, pp 293-296, issn 0957-5235, 4 p.Article

Warfarin resistance in a Chicago strain or ratsMISENHEIMER, T. M; SUTTIE, J. W.Biochemical pharmacology. 1990, Vol 40, Num 9, pp 2079-2084, issn 0006-2952, 6 p.Article

Feasibility of Implementing a Comprehensive Warfarin Pharmacogenetics ServiceNUTESCU, Edith A; DROZDA, Katarzyna; KADKOL, Shrihari S et al.Pharmacotherapy. 2013, Vol 33, Num 11, pp 1156-1164, issn 0277-0008, 9 p.Article

Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarinTEH, L. K; LANGMIA, I. M; FAZLEEN HASLINDA, M. H et al.Journal of clinical pharmacy and therapeutics (Print). 2012, Vol 37, Num 2, pp 232-236, issn 0269-4727, 5 p.Article

Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patientsLAL, Suman; SANDANARAJ, Edwin; SRINIVASA RAO JADA et al.British journal of clinical pharmacology. 2008, Vol 65, Num 2, pp 260-264, issn 0306-5251, 5 p.Article

The influence of VKORC1 3730 G > A polymorphism on warfarin dose: replyCINI, Michela; LEGNANI, Cristina; COSMI, Benilde et al.European journal of clinical pharmacology. 2013, Vol 69, Num 4, issn 0031-6970, p. 1045Article

Warfarin embryopathy: fetal manifestationsWAINWRIGHT, Helen; BEIGHTON, Peter.Virchows Archiv. 2010, Vol 457, Num 6, pp 735-739, issn 0945-6317, 5 p.Article

Effect of continuous subcutaneous Treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarinWADE, Michael; HUNT, Thomas L; LAI, Allen A et al.Journal of cardiovascular pharmacology. 2003, Vol 41, Num 6, pp 908-915, issn 0160-2446, 8 p.Article

A Polymorphism in the VKORC1 Regulator Calumenin Predicts HigherWarfarin Dose Requirements in African AmericansVOORA, D; KOBOLDT, D. C; PATEL, S. R et al.Clinical pharmacology and therapeutics. 2010, Vol 87, Num 4, pp 445-451, issn 0009-9236, 7 p.Article

Impact of VKORC1 Haplotypes on Long-Term Graft Function in Kidney TransplantationQUTEINEH, Lina; VERSTUYFT, Celine; DURRBACH, Antoine et al.Transplantation. 2008, Vol 86, Num 6, pp 779-783, issn 0041-1337, 5 p.Article

Influence of the VKORC1 3730 G > A polymorphism on warfarin doseSKOV, Jane; BLADBJERG, Else-Marie; JESPERSEN, Jørgen et al.European journal of clinical pharmacology. 2013, Vol 69, Num 4, pp 1043-1044, issn 0031-6970, 2 p.Article

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian populationLEE, Soo-Chin; NG, Swee-Siang; NG, Kheng-Siang et al.Clinical pharmacology and therapeutics. 2006, Vol 79, Num 3, pp 197-205, issn 0009-9236, 9 p.Article

Optimal initial dose adjustment of warfarin in orthopedic patientsLENZINI, Petra A; GRICE, Gloria R; GAGE, Brian F et al.The Annals of pharmacotherapy. 2007, Vol 41, Num 11, pp 1798-1804, issn 1060-0280, 7 p.Article

Warfarin-induced tracheobronchial calcificationTHOONGSUWAN, Nisa; STERN, Eric J.Journal of thoracic imaging. 2003, Vol 18, Num 2, pp 110-112, issn 0883-5993, 3 p.Article

The story of the discovery of heparin and warfarinWARDROP, Douglas; KEELING, David.British journal of haematology. 2008, Vol 141, Num 6, pp 757-763, issn 0007-1048, 7 p.Article

Probable Interaction Between Warfarin and TorsemideBIRD, Jennifer; CARMONA, Carlos.The Annals of pharmacotherapy. 2008, Vol 42, Num 12, pp 1893-1898, issn 1060-0280, 6 p.Article

WARFARIN THERAPY : INFLUENCE OF PHARMACOGENETIC AND ENVIRONMENTAL FACTORS ON THE ANTICOAGULANT RESPONSE TO WARFARINSIGURET, Virginie; PAUTAS, Eric; GOUIN-THIBAULT, Isabelle et al.Vitamins and hormones. 2008, Vol 78, pp 247-264, issn 0083-6729, 18 p.Article

Fluorescence Enhancement of Warfarin Induced by Interaction with β-CyclodextrinVASQUEZ, Jacob M; VU, Andrew; SCHULTZ, Jerome S et al.Biotechnology progress. 2009, Vol 25, Num 4, pp 906-914, issn 8756-7938, 9 p.Conference Paper

Reversible endotension associated with excessive warfarin anticoagulationIYER, Vikram S; MACKENZIE, Kent S; CORRIVEAU, Marc-Michel et al.Journal of vascular surgery. 2007, Vol 45, Num 3, pp 600-602, issn 0741-5214, 3 p.Article

Solving the mystery of excessive warfarin-induced bleeding: A personal historical perspectiveHIRSH, Jack.Thrombosis and haemostasis. 2014, Vol 112, Num 5, pp 853-856, issn 0340-6245, 4 p.Article